On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence-论文-万方医学网

首页> > On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence

On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence

导出原文传递

翻译打印收藏纠错

第一作者： Karen Jaqueline,Paredes-Ruiz

作者： Karen Jaqueline,Paredes-Ruiz ^[1] ; Karla,Chavira-Ramos ^[2] ; Mario,Orozco-Morales ^[3] ; Cimen,Karasu ^[4] ; Alexey A,Tinkov ^[5] ; Michael,Aschner ^[6] ; Abel,Santamaría ; Ana Laura,Colín-González

作者单位： Laboratorio Clínico,Instituto Nacional de Cancerología ^[1] Unidad Funcional de Oncología Torácica Y Laboratorio de Medicina Personalizada, Instituto Nacional ^[2] Facultad de Ciencias,Universidad Nacional Autónoma de México ^[3] IM Sechenov First Moscow State Medical University (Sechenov University) ^[4] Laboratorio de Aminoácidos Excitadores/Laboratorio de Neurofarmacología Molecular Y Nanotecnología ^[5] Cellular Stress Response and Signal Transduction Research Laboratory, Department of Medical ^[6]

关键词 Anandamide 2-Aranchidonoylglycerol Endocannabinoid system Endocannabinoid metabolism FAAH inhibitors MAGL inhibitors

发布时间 2022-04-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence

相似文献

同项目论文

相关期刊

检索历史 清除

On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence

相似文献

同项目论文

相关期刊

检索历史清除